125 related articles for article (PubMed ID: 7713133)
21. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
[TBL] [Abstract][Full Text] [Related]
22. Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan.
Tsai YS; Tzai TS; Chow NH; Yang WH; Tong YC; Lin JS; Chang CC; Cheng HL; Lin YM
Urol Int; 2003; 71(3):262-70. PubMed ID: 14512646
[TBL] [Abstract][Full Text] [Related]
23. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.
Lipponen P; Eskelinen M
Br J Cancer; 1994 Jun; 69(6):1120-5. PubMed ID: 7911031
[TBL] [Abstract][Full Text] [Related]
24. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder.
Liu L; Zhu D; Gao R; Guo H
Urol Int; 2008; 81(1):72-6. PubMed ID: 18645275
[TBL] [Abstract][Full Text] [Related]
25. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas.
Kakehi Y; Ozdemir E; Habuchi T; Yamabe H; Hashimura T; Katsura Y; Yoshida O
Jpn J Cancer Res; 1998 Feb; 89(2):214-20. PubMed ID: 9548450
[TBL] [Abstract][Full Text] [Related]
26. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
27. Florid von Brunn nests mimicking urothelial carcinoma: a morphologic and immunohistochemical comparison to the nested variant of urothelial carcinoma.
Volmar KE; Chan TY; De Marzo AM; Epstein JI
Am J Surg Pathol; 2003 Sep; 27(9):1243-52. PubMed ID: 12960809
[TBL] [Abstract][Full Text] [Related]
28. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
29. p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression.
Soini Y; Turpeenniemi-Hujanen T; Kamel D; Autio-Harmainen H; Risteli J; Risteli L; Nuorva K; Pääkkö P; Vähäkangas K
Br J Cancer; 1993 Nov; 68(5):1029-35. PubMed ID: 8217593
[TBL] [Abstract][Full Text] [Related]
30. [Expression of protein p53 in superficial transitional carcinoma of the bladder with differing course].
Rebassa Llull M; Gutiérrez Sanz-Gadea C; Muñoz Vélez D; Esteva Bauzá M; Gómez Bellvert C; Mus Malleu A; Riera Marí V; Hidalgo Pardo F; Torrens Darder I; Ozonas Moragues M
Arch Esp Urol; 1999 Dec; 52(10):1061-4. PubMed ID: 10680229
[TBL] [Abstract][Full Text] [Related]
31. Mucinous adenocarcinoma of the renal pelvis associated with transitional cell carcinoma in the renal pelvis and the bladder.
Takehara K; Nomata K; Eguchi J; Hisamatsu H; Maruta S; Hayashi T; Koga S; Kanetake H
Int J Urol; 2004 Nov; 11(11):1016-8. PubMed ID: 15509208
[TBL] [Abstract][Full Text] [Related]
32. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
[TBL] [Abstract][Full Text] [Related]
33. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2.
Vollmer RT; Humphrey PA; Swanson PE; Wick MR; Hudson ML
Cancer; 1998 Feb; 82(4):715-23. PubMed ID: 9477105
[TBL] [Abstract][Full Text] [Related]
34. Predictors of outcome in small cell carcinoma of the cervix--a case series.
Straughn JM; Richter HE; Conner MG; Meleth S; Barnes MN
Gynecol Oncol; 2001 Nov; 83(2):216-20. PubMed ID: 11606074
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical study of neuroendocrine differentiation in primary glandular lesions and tumors of the urinary bladder.
Bollito ER; Pacchioni D; Lopez-Beltran A; Volante M; Terrone C; Casetta G; Mari M; DePompa R; Cappia S; Papotti M
Anal Quant Cytol Histol; 2005 Aug; 27(4):218-24. PubMed ID: 16220833
[TBL] [Abstract][Full Text] [Related]
36. Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder.
Imai T; Kimura M; Takeda M; Tomita Y
Br J Cancer; 1995 Jan; 71(1):69-72. PubMed ID: 7819052
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
38. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
Krüger S; Lange I; Kausch I; Feller AC
Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
[TBL] [Abstract][Full Text] [Related]
39. WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer.
Korkolopoulou P; Konstantinidou AE; Thomas-Tsagli E; Christodoulou P; Kapralos P; Davaris P
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):285-92. PubMed ID: 11127920
[TBL] [Abstract][Full Text] [Related]
40. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma.
Sato K; Moriyama M; Mori S; Saito M; Watanuki T; Terada K; Okuhara E; Akiyama T; Toyoshima K; Yamamoto T
Cancer; 1992 Nov; 70(10):2493-8. PubMed ID: 1358427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
